Rosetta Genomics this week announced that its previously announced license and collaboration deal with Prometheus Laboratories has closed.
The deal, unveiled earlier this month, gives Prometheus the US market rights to Rosetta's three microRNA-based diagnostics, including miRview Meso, which differentiates lung cancer from mesothelioma; miRview Mets, which is designed to determine the source of cancers of unknown primary origin; and miRview Squamous, which is designed to differentiate squamous from non-squamous non-small cell lung cancer (see RNAi News, 4/16/2009).
As part of the deal, Rosetta and Prometheus will also jointly develop two additional miRNA-based gastroenterology diagnostics.
The companies also said that Prometheus' planned purchase of 2 million shares of Rosetta at $4 per share has been completed.